{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/epistaxis-nosebleeds/management/recurrent-epistaxis/","result":{"pageContext":{"chapter":{"id":"49c8979b-9af3-5eab-a574-05004fda4a4a","slug":"recurrent-epistaxis","fullItemName":"Scenario: Recurrent epistaxis","depth":2,"htmlHeader":"<!-- begin field b876ea84-76bd-4baf-939c-33aa0def2e28 --><h2>Scenario: Recurrent epistaxis</h2><!-- end field b876ea84-76bd-4baf-939c-33aa0def2e28 -->","summary":"Covers the management of recurrent episodes of epistaxis in people who are currently asymptomatic.","htmlStringContent":"<!-- begin item 7c817382-99c1-4217-8657-d63d01bf7a99 --><!-- begin field f0cb2740-9e77-402b-a2d0-acbc0158701f --><p>From age 1 month onwards.</p><!-- end field f0cb2740-9e77-402b-a2d0-acbc0158701f --><!-- end item 7c817382-99c1-4217-8657-d63d01bf7a99 -->","topic":{"id":"41f6c6fa-463d-5a28-9ffa-15f68320f0ad","topicId":"4e494407-5d2a-47b0-8980-124980c278b3","topicName":"Epistaxis (nosebleeds)","slug":"epistaxis-nosebleeds","lastRevised":"Last revised in August 2020","chapters":[{"id":"8924b1cb-1830-5e93-a601-5a515e1ef05c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"7267ef2e-a210-5137-a813-dac8e91b1831","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b0e06988-22ae-5f73-bb20-2033460ee20a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"fb00e926-a8d3-5ae8-8f15-5dca94fff64d","slug":"changes","fullItemName":"Changes"},{"id":"a4dfa534-2e88-5962-97a7-50f5bc6903c5","slug":"update","fullItemName":"Update"}]},{"id":"182f787a-708c-5014-9591-48eddb54268d","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bcaf0313-1bdc-548f-971f-dc9159fb2738","slug":"goals","fullItemName":"Goals"},{"id":"1820dda9-b7b1-5247-ad00-826f0b3f4c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"6508b703-ccd2-56fe-b323-3dfd267f6057","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"27ddc66a-0532-592f-be80-40b6581b9e9c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d6beda29-ddc7-569c-8f25-2395cd0b3213","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"9b9f6fbd-0722-5dcc-afac-e879fdfc6832","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"1c7c7c7b-4f02-5cb0-af91-12ff20526fa7","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"6a3ef102-679b-5a9e-9d3d-73b58b70d2ef","slug":"definition","fullItemName":"Definition"},{"id":"05e8d25d-b629-5896-847e-76ab44c33576","slug":"causes","fullItemName":"Causes"},{"id":"7e0e17b8-b890-541e-92b5-0790ae3d08b5","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2624ce06-f85b-541e-a7bb-589ee1197b08","slug":"prognosis","fullItemName":"Prognosis"},{"id":"7f96f0b5-4a51-5413-b0b1-73ea61f581ac","slug":"complications","fullItemName":"Complications"}]},{"id":"eee7ea0d-538e-53b8-bf4c-3333153a7978","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ac070a5-a9e9-58a1-a125-c8a457f1833a","slug":"assessment","fullItemName":"Assessment"}]},{"id":"662dfd0d-d907-52ea-8d8b-97a3cf464cc7","fullItemName":"Management","slug":"management","subChapters":[{"id":"e0220daa-0b07-5f92-af4d-9530f90352ea","slug":"acute-epistaxis","fullItemName":"Scenario: Acute epistaxis"},{"id":"49c8979b-9af3-5eab-a574-05004fda4a4a","slug":"recurrent-epistaxis","fullItemName":"Scenario: Recurrent epistaxis"}]},{"id":"91147d78-80c8-5364-b3e1-7995b6718b2a","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c7a65cbb-e7c2-50f8-b6a2-68a41e1db4cb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bb7e51c5-d888-5640-8c0b-07c8a505bf48","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3c48404f-ce42-5815-8d02-6dd6ef1ae5f3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"b82f78a8-0e22-5156-bc34-baaa9c78ee15","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"6093800a-eb2a-53e5-918a-e8f0be8c4ae0","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6ce6588e-beaa-5a3b-a424-cfad9a225022","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"1343761f-c431-50df-9bd2-a9b600c5e067","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"662dfd0d-d907-52ea-8d8b-97a3cf464cc7","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"4030e05a-d326-5799-b0e5-ec363d5e9099","slug":"management-of-recurrent-epistaxis","fullItemName":"Management of recurrent epistaxis","depth":3,"htmlHeader":"<!-- begin field 08056692-9e1b-4614-bb0d-6a3ba663b58e --><h3>How should I manage a person with recurrent epistaxis who is currently asymptomatic?</h3><!-- end field 08056692-9e1b-4614-bb0d-6a3ba663b58e -->","summary":null,"htmlStringContent":"<!-- begin item 8981482f-a4ae-433c-9c33-2d69c70f6ad3 --><!-- begin field 16247c97-6775-4e6e-baf5-6b0856fa3976 --><ul><li><strong>Advise the person on first aid measures to control bleeding during an acute episode, and self-care measures to be used afterwards to prevent re-bleeding. </strong></li><li><strong>Recommend that during a nosebleed they:</strong><ul><li>Sit with their upper body tilted forward and their mouth open.</li><li>Avoid lying down, unless they are feeling faint.</li><li>Pinch the cartilaginous (soft) part of the nose firmly and hold it for 10–15 minutes without releasing the pressure, whilst breathing through their mouth.</li></ul></li><li><strong>Recommend that for 24 hours after a nosebleed they avoid:</strong><ul><li>Blowing or picking the nose.</li><li>Heavy lifting.</li><li>Strenuous exercise.</li><li>Lying flat.</li><li>Drinking alcohol or hot drinks.</li></ul></li><li><strong>Offer the person written information on epistaxis.</strong> A patient information leaflet is available from <a data-hyperlink-id=\"e97cf4ac-ae73-49e9-9e17-aac80159a9cf\" href=\"https://www.entuk.org/sites/default/files/files/ENT/About%20Epistaxis%206pp%20DL%20(09021)_7_16.pdf\">ENT UK</a>.</li><li><strong>Determine if there is an <a class=\"topic-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/background-information/causes/\">underlying cause</a> for epistaxis.</strong><ul><li>Consider arranging a full blood count for adults with recurrent epistaxis.</li><li>Be aware that an underlying cause is likely in children younger than 2 years of age.</li></ul></li><li><strong>Consider referral to an ear, nose, and throat specialist if a person has recurrent episodes of epistaxis and signs and symptoms suggestive of a serious underlying cause, such as:</strong><ul><li><strong>Angiofibroma</strong> (rare benign nasal tumour, usually in males aged 12–20 years of age) — suggested by nasal obstruction and severe epistaxis.</li><li><strong>Cancer </strong>— suggested by nasal obstruction, facial pain, hearing loss, eye symptoms (proptosis or double vision), and/or persistent lymphadenopathy.<ul><li>Be aware that nasal, sinus, and nasopharyngeal cancers are most common in people older than 50 years of age, in those with occupational exposure to wood dust or chemicals, and (for nasopharyngeal cancer) in people of South Chinese or North African family origin.</li></ul></li><li><strong>Telangiectasia</strong> — suggested by red or purple spots on the fingertip pads, lips, lining of the nose, and occasionally the ears and face. There may be a family history of hereditary haemorrhagic telangiectasia.</li></ul></li><li><strong>Consider referral to a paediatrician for children younger than 2 years of age who present with epistaxis to rule out an underlying cause. Also, consider the possibility of maltreatment. For further information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/child-maltreatment-recognition-management/\">Child maltreatment - recognition and management</a>.</strong></li><li><strong>If the person is <em>not </em>at high risk of having a serious underlying cause, </strong>discuss treatment options for recurrent epistaxis. These include:<ul><li>Topical treatment with an antiseptic preparation to reduce crusting and vestibulitis.<ul><li>Prescribe Naseptin<sup>® </sup>(chlorhexidine and neomycin) cream to be applied to the nostrils four times daily for 10 days. If compliance is a problem, advise that it can be used twice daily for up to 2 weeks.</li><li>If the person is allergic to neomycin, peanut, or soya, do not prescribe Naseptin<sup>®</sup>. Consider prescribing mupirocin nasal ointment to be applied to the nostrils two to three times a day for 5–7 days.</li></ul></li><li><a class=\"topic-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/management/acute-epistaxis/#nasal-cautery\">Nasal cautery</a>. This is similarly effective to Naseptin<sup>® </sup>antiseptic cream but may be more uncomfortable. Consider it for use in primary care only if:<ul><li>The appropriate expertise and facilities (good lighting, topical anaesthetic spray, and nasal speculum) are available, <em>and</em></li><li>The bleeding point can be identified, <em>and</em></li><li>It can be tolerated (for example adults and older children, but not younger children).</li></ul></li></ul></li></ul><!-- end field 16247c97-6775-4e6e-baf5-6b0856fa3976 --><!-- end item 8981482f-a4ae-433c-9c33-2d69c70f6ad3 -->","subChapters":[{"id":"20ff1417-0d36-50ba-a9d6-d562d3373866","slug":"basis-for-recommendation-ce8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field aaf85597-b232-4655-9daf-02b3bb867cca --><h4>Basis for recommendation</h4><!-- end field aaf85597-b232-4655-9daf-02b3bb867cca -->","summary":null,"htmlStringContent":"<!-- begin item ce88b539-805a-4b9c-af2d-9f3fda3cb56a --><!-- begin field 2a5e3bef-e114-49dd-b68d-f9110e514c29 --><p>The recommendations on management of recurrent epistaxis are based on expert opinion within an American guideline <em>Epistaxis: an overview</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Kasperek and Pollock, 2013</a>], the BMJ Best Practice Guideline <em>Epistaxis </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">BMJ Best Practice, 2018</a>], and a number of narrative review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Pashen and Stevens, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Wormald, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Crown and Criner, 2004</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Aneeshkumar et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Kucik and Clenney, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Leong et al, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Pope and Hobbs, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Daudia et al, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Schlosser, 2009</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Mulla et al, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Patel and Fowell, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Jayakody, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Womack et al, 2018</a>].</p><h5>Epistaxis in children younger than 2 years of age</h5><ul><li>Epistaxis is rare in children under 2 years of age and an underlying cause such as injury or coagulopathy should, therefore, be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Patel et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Siddiq and Grainger, 2015</a>].</li><li>A retrospective analysis of Accident and Emergency department attendance records and hospital admissions reported 16 cases of nose bleed within this age group. In 8 cases, bleeding was associated with visible trauma; in 4 cases with thrombocytopenia (secondary to malignancy in 3 cases); in 2 cases with an associated apparent life-threatening event; and in 2 cases with an upper respiratory tract infection. [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">McIntosh et al, 2007</a>].</li><li>Epistaxis in children under 2 years of age is significantly associated with asphyxiation (unintentional or intentional). A meta-analysis of four studies found that the probability of asphyxiation in a child under two years old with epistaxis is 19.6% (95% CI, 12.7-28.8%) and descrbed the features associated with asphyxiation for those with epistaxis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">RCPCH, 2017</a>]. </li></ul><h5>Topical treatments</h5><ul><li>The recommendation to prescribe a topical antiseptic preparation is based on the opinion of a previous expert reviewer of this CKS topic, who suggested that as well as their antimicrobial action, topical treatments can act as a barrier to further trauma and preserve the humidity of the lining of the nose.</li><li>The suggested four times a day dosing regimen for Naseptin<sup>® </sup>(chlorhexidine and neomycin) cream derives from the manufacturer's Summary of Product Characteristic (SPC) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">ABPI, 2017a</a>], but it was the opinion of previous CKS expert reviewers of this topic that a twice-daily regimen for up to 2 weeks is acceptable if compliance is an issue.</li><li>The manufacturer of Naseptin<sup>® </sup>cream advises that it should be avoided in people with a peanut allergy as it contains arachis oil (peanut oil). As there is a possible relationship between allergy to peanut and allergy to soya, people with soya allergy should also avoid Naseptin<sup>® </sup>cream [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">ABPI, 2017a</a>].</li><li>The suggested dosing regimen for mupirocin nasal ointment is taken from the manufacturer's SPC [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">ABPI, 2017b</a>].</li><li>However, the available evidence is limited regarding the effectiveness of topical treatments for <em>recurrent</em> epistaxis.<ul><li>A Cochrane systematic review of interventions for recurrent idiopathic epistaxis in children identified one very low-quality randomized controlled trial (RCT) that compared Naseptin<sup>®</sup>antiseptic cream with no treatment in children (n = 88) with recurrent epistaxis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Qureishi and Burton, 2012</a>]. The evidence showed that Naseptin<sup>® </sup>cream may be more effective than no treatment for complete resolution of bleeding at 8 weeks, but it was unclear whether it reduces the number of post-treatment bleeding episodes.</li><li>Two small RCTs that assessed outcomes in 64 adults [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Murthy et al, 1999</a>]  and 48 children [<a class=\"bibliography-reference internal-reference\" href=\"/topics/epistaxis-nosebleeds/references/\">Qureishi and Burton, 2012</a>] showed that Naseptin<sup>® </sup>antiseptic cream (used twice daily) and silver nitrate cautery are of similar efficacy in improving symptoms of recurrent epistaxis.</li></ul></li></ul><!-- end field 2a5e3bef-e114-49dd-b68d-f9110e514c29 --><!-- end item ce88b539-805a-4b9c-af2d-9f3fda3cb56a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}